BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 26739837)

  • 1. Reduced Plasma Levels of sCD14 and I-FABP in HIV-infected Patients with Mesalazine-treated Ulcerative Colitis.
    Michelini Z; Baroncelli S; Fantauzzi A; Pasquale C; Galluzzo CM; Sanchez M; Gatto M; Amici R; Franco M; d'Ettorre G; Fimiani C; Mezzaroma I; Vullo V; Merli M; Palmisano L
    HIV Clin Trials; 2016 Mar; 17(2):49-54. PubMed ID: 26739837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Co-Trimoxazole on Microbial Translocation in HIV-1-Infected Patients Initiating Antiretroviral Therapy.
    Vesterbacka J; Barqasho B; Häggblom A; Nowak P
    AIDS Res Hum Retroviruses; 2015 Aug; 31(8):830-6. PubMed ID: 26059763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble CD14 in cerebrospinal fluid is associated with markers of inflammation and axonal damage in untreated HIV-infected patients: a retrospective cross-sectional study.
    Jespersen S; Pedersen KK; Anesten B; Zetterberg H; Fuchs D; Gisslén M; Hagberg L; Trøseid M; Nielsen SD
    BMC Infect Dis; 2016 Apr; 16():176. PubMed ID: 27103116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of MMX mesalazine on disease-specific health-related quality of life in ulcerative colitis patients.
    Solomon D; Yarlas A; Hodgkins P; Karlstadt R; Yen L; Kane S
    Aliment Pharmacol Ther; 2012 Jun; 35(12):1386-96. PubMed ID: 22536781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating interleukin-6 levels correlate with residual HIV viraemia and markers of immune dysfunction in treatment-controlled HIV-infected patients.
    Bastard JP; Soulié C; Fellahi S; Haïm-Boukobza S; Simon A; Katlama C; Calvez V; Marcelin AG; Capeau J
    Antivir Ther; 2012; 17(5):915-9. PubMed ID: 22436412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of new-onset ulcerative colitis and ulcerative proctitis: a retrospective study.
    Richter JM; Kushkuley S; Barrett JA; Oster G
    Aliment Pharmacol Ther; 2012 Aug; 36(3):248-56. PubMed ID: 22690748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ulcerative colitis patients with an inflammatory response upon mesalazine cannot be desensitized: a randomized study.
    Buurman DJ; De Monchy JG; Schellekens RC; van der Waaij LA; Kleibeuker JH; Dijkstra G
    Scand J Gastroenterol; 2015 Apr; 50(4):399-405. PubMed ID: 25633468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma intestinal fatty acid-binding protein fails to predict endoscopic disease activity in inflammatory bowel disease patients.
    Bodelier AG; Pierik MJ; Lenaerts K; de Boer E; Olde Damink SW; Hameeteman WM; Masclee AA; Jonkers DM
    Eur J Gastroenterol Hepatol; 2016 Jul; 28(7):807-13. PubMed ID: 26919325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intestinal Barrier Impairment and Immune Activation in HIV-Infected Advanced Late Presenters are Not Dependent on CD4 Recovery.
    Wójcik-Cichy K; Piekarska A; Jabłonowska E
    Arch Immunol Ther Exp (Warsz); 2018 Aug; 66(4):321-327. PubMed ID: 29468256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Interplay Between Host Genetic Variation, Viral Replication, and Microbial Translocation in Untreated HIV-Infected Individuals.
    Perkins MR; Bartha I; Timmer JK; Liebner JC; Wolinsky D; Günthard HF; Hauser C; Bernasconi E; Hoffmann M; Calmy A; Battegay M; Telenti A; Douek DC; Fellay J;
    J Infect Dis; 2015 Aug; 212(4):578-84. PubMed ID: 25701868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low levels of microbial translocation marker LBP are associated with sustained viral response after anti-HCV treatment in HIV-1/HCV co-infected patients.
    Nyström J; Stenkvist J; Häggblom A; Weiland O; Nowak P
    PLoS One; 2015; 10(3):e0118643. PubMed ID: 25785448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD4+ immune response as a potential biomarker of patient reported inflammatory bowel disease (IBD) activity.
    Brandhorst G; Weigand S; Eberle C; Raddatz D; Karaus M; Oellerich M; Walson PD
    Clin Chim Acta; 2013 Jun; 421():31-3. PubMed ID: 23485644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis.
    Flourié B; Hagège H; Tucat G; Maetz D; Hébuterne X; Kuyvenhoven JP; Tan TG; Pierik MJ; Masclee AA; Dewit O; Probert CS; Aoucheta D;
    Aliment Pharmacol Ther; 2013 Apr; 37(8):767-75. PubMed ID: 23451806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study.
    Marteau P; Probert CS; Lindgren S; Gassul M; Tan TG; Dignass A; Befrits R; Midhagen G; Rademaker J; Foldager M
    Gut; 2005 Jul; 54(7):960-5. PubMed ID: 15951542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early symptomatic response and mucosal healing with mesalazine rectal suspension therapy in active distal ulcerative colitis--additional results from two controlled studies.
    Sandborn WJ; Hanauer S; Lichtenstein GR; Safdi M; Edeline M; Scott Harris M
    Aliment Pharmacol Ther; 2011 Oct; 34(7):747-56. PubMed ID: 21848857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study.
    D'Haens G; Hommes D; Engels L; Baert F; van der Waaij L; Connor P; Ramage J; Dewit O; Palmen M; Stephenson D; Joseph R
    Aliment Pharmacol Ther; 2006 Oct; 24(7):1087-97. PubMed ID: 16984503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mucosal CXCR4+ IgG plasma cells contribute to the pathogenesis of human ulcerative colitis through FcγR-mediated CD14 macrophage activation.
    Uo M; Hisamatsu T; Miyoshi J; Kaito D; Yoneno K; Kitazume MT; Mori M; Sugita A; Koganei K; Matsuoka K; Kanai T; Hibi T
    Gut; 2013 Dec; 62(12):1734-44. PubMed ID: 23013725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Th17/Treg ratio, IL-1RA and sCD14 levels in primary HIV infection predict the T-cell activation set point in the absence of systemic microbial translocation.
    Chevalier MF; Petitjean G; Dunyach-Rémy C; Didier C; Girard PM; Manea ME; Campa P; Meyer L; Rouzioux C; Lavigne JP; Barré-Sinoussi F; Scott-Algara D; Weiss L
    PLoS Pathog; 2013; 9(6):e1003453. PubMed ID: 23818854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating memory B cells and plasmablasts are associated with the levels of serum immunoglobulin in patients with ulcerative colitis.
    Wang X; Jiang Y; Zhu Y; Zhang M; Li M; Wang H; Gao P
    J Cell Mol Med; 2016 May; 20(5):804-14. PubMed ID: 26800315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma levels of soluble CD14 independently predict mortality in HIV infection.
    Sandler NG; Wand H; Roque A; Law M; Nason MC; Nixon DE; Pedersen C; Ruxrungtham K; Lewin SR; Emery S; Neaton JD; Brenchley JM; Deeks SG; Sereti I; Douek DC;
    J Infect Dis; 2011 Mar; 203(6):780-90. PubMed ID: 21252259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.